(Reuters) – Pfizer Inc said on Monday U.S. regulators declined to approve the company’s biosimilar of Roche’s blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.
(Reuters) – Pfizer Inc said on Monday U.S. regulators declined to approve the company’s biosimilar of Roche’s blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.